SEPHS1P1

Across TCGA pan-cancer cohorts, SEPHS1P1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SEPHS1P1 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SEPHS1P1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SEPHS1P1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, DLBC, and UCEC are the cancer types where SEPHS1P1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	III,IV	0.076	0.360	.001	18	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.791	0.463	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SEPHS1P1–LIHC (DFS)

Open the LIHC breakdown →